Cosopt PF®
Dorzolamide 2% / Timolol 0.5% · ophthalmic solution
Antiglaucoma
Approved uses
Elevated IOP in open-angle glaucoma or ocular hypertension inadequately controlled on a beta-blocker
1 drop in the affected eye(s) BID
Adds a further 14% to 20% IOP reduction over timolol alone, sustained through 8 hours.
OFF-LABELNot in the FDA label for this product
IOP spike prophylaxis before intravitreal anti-VEGF injection
1 drop 1 hour before the injection; a 2-drop regimen of 1 drop at 1 hour and 1 drop at 5 minutes before was also studied
Controlled trial · n=89
Randomized, double-masked trial, 308 patients contributing one eye each, of which 89 received dorzolamide/timolol: mean IOP at 30 minutes post-injection stayed within 21 mmHg and was back to baseline at 1 hour, while the untreated group rose 7.84 mmHg at 30 minutes and remained 4.05 mmHg above baseline at 1 hour. The trial named the preserved product, not this preservative-free presentation; premedication blunted rather than abolished the spike (still up 2.31 mmHg with one drop and 1.71 mmHg with two at 30 minutes), and the 32 controls were not randomized but were patients excluded from the drug arms for allergy or contraindication.
Contraindications
- Bronchial asthma or a history of bronchial asthma.
- Severe chronic obstructive pulmonary disease.
- Sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, or cardiogenic shock.
- Hypersensitivity to any component of this product.
Dorzolamide 2% (20 mg/mL) and timolol 0.5% (5 mg/mL) preservative-free solution, 0.2 mL single-dose containers, package of 60
Fixed combination of dorzolamide, a human carbonic anhydrase II inhibitor, and timolol, a nonselective beta-1 and beta-2 adrenergic blocker without significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity; each component reduces aqueous humor secretion. Given BID the pair lowers IOP more than either component alone, but not as much as dorzolamide TID plus timolol BID administered concomitantly.
Warnings & Precautions
- Potentiation of respiratory reactions including asthma: Timolol is absorbed systemically from topical dosing, so reactions attributable to systemic beta-blockers may occur. Severe respiratory reactions including death due to bronchospasm in patients with asthma, and rarely death associated with cardiac failure, have been reported after systemic or ophthalmic timolol.
- Cardiac failure: Sympathetic stimulation may be essential to support the circulation in individuals with diminished myocardial contractility, and beta-blockade may precipitate more severe failure. In patients without a history of cardiac failure, continued depression of the myocardium over time can, in some cases, lead to cardiac failure. Discontinue at the first sign or symptom.
- Sulfonamide hypersensitivity: Dorzolamide is a sulfonamide that is absorbed systemically despite topical dosing, so the reactions attributable to sulfonamides may occur, rarely fatal, including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias. Sensitization may recur when a sulfonamide is readministered by any route; discontinue if a serious reaction or hypersensitivity occurs.
- Obstructive pulmonary disease: Patients with mild or moderate COPD, bronchospastic disease, or a history of bronchospastic disease should in general not receive beta-blockers; asthma, a history of asthma, and severe COPD are contraindications.
- Increased reactivity to allergens: Patients with a history of atopy or of severe anaphylaxis may be more reactive to allergen challenge while on a beta-blocker and may be unresponsive to the usual doses of epinephrine.
- Potentiation of muscle weakness: Beta-blockade has been reported to potentiate myasthenic symptoms such as diplopia, ptosis, and generalized weakness, and timolol has been reported rarely to increase muscle weakness in some patients with myasthenia gravis or myasthenic symptoms.
- Masking of hypoglycemic symptoms: Beta-blockers may mask the signs and symptoms of acute hypoglycemia; use caution in patients subject to spontaneous hypoglycemia and in diabetic patients (especially those with labile diabetes) on insulin or oral hypoglycemic agents.
- Masking of thyrotoxicosis: Beta-blockers may mask tachycardia and other signs of hyperthyroidism, and abrupt withdrawal may precipitate thyroid storm.
- Renal and hepatic impairment: Not studied in severe renal impairment (CrCl below 30 mL/min) and not recommended there, since dorzolamide and its metabolite are excreted predominantly by the kidney; not studied in hepatic impairment, so use with caution there.
- Impairment of beta-adrenergic reflexes during surgery: Blockade impairs the ability of the heart to respond to beta-adrenergically mediated reflex stimuli, which may augment the risk of general anesthesia. Some patients have experienced protracted severe hypotension during anesthesia, and difficulty restarting and maintaining the heartbeat has been reported.
- Corneal edema: Carbonic anhydrase activity is present in the corneal endothelium, and patients with low endothelial cell counts have an increased potential for developing corneal edema; use caution when prescribing to this group of patients.
- Single-dose container handling: No preservative, so sterility is not maintained after a unit is opened; discard the remaining contents immediately and discard unused containers 15 days after the foil pouch is first opened.
- Additive carbonic anhydrase inhibition: Concomitant use of oral carbonic anhydrase inhibitors is not recommended; the systemic effects of carbonic anhydrase inhibition are potentially additive.
- Additive effects of beta-blockade: Observe for potential additive systemic and IOP beta-blockade with an oral beta-blocker; two topical beta-blockers are not recommended. Potentiated systemic beta-blockade has been reported with CYP2D6 inhibitors such as quinidine and SSRIs.
- Atrioventricular conduction disturbances and hypotension: Use caution when coadministering oral or intravenous calcium antagonists because of possible atrioventricular conduction disturbances, left ventricular failure, and hypotension, and avoid coadministration in patients with impaired cardiac function. With digitalis and calcium antagonists, beta-blockers may have additive effects in prolonging atrioventricular conduction time.
- Hypotension and/or marked bradycardia: With catecholamine-depleting drugs such as reserpine, close observation is recommended because of possible additive effects and the production of hypotension and/or marked bradycardia, which may result in vertigo, syncope, or postural hypotension.
Common Side Effects
The most frequent adverse reactions (up to 30% of patients) were taste perversion (bitter, sour, or unusual taste) and ocular burning and/or stinging. Conjunctival hyperemia, blurred vision, superficial punctate keratitis, or eye itching occurred in 5% to 15%. Reactions in 1% to 5% included blepharitis, conjunctivitis, corneal erosion, dryness of eyes, headache, and nausea. With timolol, arrhythmia, syncope, bronchospasm (predominantly in patients with pre-existing bronchospastic disease), increased signs of myasthenia gravis, and ptosis have been reported; with dorzolamide, angioedema, contact dermatitis, and transient myopia. Bradycardia, cardiac failure, Stevens-Johnson syndrome, and choroidal detachment following filtration surgery were reported postapproval, where it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Pregnancy: There are no adequate and well-controlled studies in pregnant women to inform a drug-associated risk, and no evidence of teratogenicity has been observed in mice, rats, and rabbits with dorzolamide or timolol at clinically relevant doses. Oral dorzolamide in pregnant rabbits at 2.5 mg/kg/day and above (31 times the recommended human ophthalmic dose) caused vertebral body malformations at doses that also caused maternal metabolic acidosis and decreased fetal weights, with no treatment-related malformations at 1 mg/kg/day (13 times); timolol showed no fetal malformations in mice, rats, or rabbits at oral doses up to 50 mg/kg/day.
Lactation: It is not known whether dorzolamide or timolol is excreted in human milk. Use caution in a nursing woman, and weigh the benefits of breastfeeding against the mother's clinical need for the drug and any potential adverse effects on the breastfed child.
Safety and effectiveness of the individual components are established at 2 years and older; not established below 2 years.